Top Markets
Coin of the day
Myriad Genetics, Inc. Myriad Genetics, Inc.

Myriad Genetics, Inc.

MYGN
Ранг среди акций #16435
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company,... Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Цена акции
$3.12
Последняя синхронизация: 2026-09-01
Рыночная капитализация
$294.21M
Изменение (1 день)
-3.26%
Изменение (1 год)
-54.86%
Страна
US
Торговля Myriad Genetics, Inc. (MYGN)

Категория

Коэффициент P/B для Myriad Genetics, Inc. (MYGN)
Коэффициент P/B на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций Myriad Genetics, Inc., текущий коэффициент P/B (TTM) составляет 0. В конце 2026 он составлял 0.
История P/B для Myriad Genetics, Inc. с 2026 по 2026
Коэффициент P/B в конце каждого года
Год P/B Изменить
Недостаточно данных для указанных дат.
Коэффициент P/B для аналогичных компаний или конкурентов
Компания P/B Разница P/B Страна
4.346 -
US
2.8646 -
US
- -
CN
25.3254 -
US
27.6506 -
US